Eloxx Pharmaceuticals (NASDAQ: ELOX) has received orphan drug designation from the FDA for its product ELX-02, aimed at treating cystic fibrosis. This designation supports the development of treatments for rare diseases impacting fewer than 200,000 U.S. patients. Benefits include seven years of market exclusivity post-approval and exemption from FDA application fees. Eloxx has resumed Phase 2 clinical trials in Israel and Europe, while U.S. trials remain paused due to COVID-19. CEO Gregory Williams highlighted this as a potential value inflection point for the company.
Eloxx Pharmaceuticals (NASDAQ: ELOX) announced that CEO Dr. Gregory Williams will present and hold one-on-one meetings at the 40th Annual Canaccord Genuity Virtual Growth Conference on August 13, 2020, at 4:00 PM ET. The presentation will cover Eloxx's development of novel therapeutics aimed at treating cystic fibrosis and other diseases caused by nonsense mutations. Investors can access the live webcast through the company’s website, with a replay available afterward. Eloxx focuses on developing drugs to address rare genetic disorders.
Eloxx Pharmaceuticals (NASDAQ: ELOX) announced it will release its second quarter 2020 financial results on August 6, 2020. The conference call is scheduled for 2:00 p.m. ET and will be accessible via a live webcast on the company’s website. Eloxx specializes in developing RNA-modulating drug candidates aimed at treating cystic fibrosis and other diseases caused by nonsense mutations in protein synthesis. Their lead candidate, ELX-02, is still in early clinical development. The company's recent efforts have also included a new program focused on rare ocular genetic disorders.
Eloxx Pharmaceuticals (NASDAQ: ELOX) announced the publication of a scientific manuscript on ELX-02 in the Journal of Pharmacology and Experimental Therapeutics. The study highlights ELX-02's ability to mediate read-through of premature stop codons while preserving the integrity of native stop codons. This indicates a favorable tolerability profile, as demonstrated in preclinical and clinical datasets. ELX-02 is currently undergoing Phase 2 clinical trials for cystic fibrosis patients with nonsense mutations, a crucial area with limited treatment options.
Eloxx Pharmaceuticals (NASDAQ: ELOX) announced the resumption of enrollment in its Phase 2 clinical trial for ELX-02, aimed at treating cystic fibrosis, in Israel and Europe after a COVID-19-related pause. The U.S. trial remains on hold, prioritizing health and safety. CEO Dr. Gregory Williams expressed commitment to completing enrollment and reporting top-line data promptly. ELX-02 targets rare diseases caused by nonsense mutations, a significant advancement in treating cystic fibrosis and other genetic disorders.
Eloxx Pharmaceuticals (NASDAQ: ELOX) provided a business update and financial results for Q1 2020. The company is committed to completing its Phase 2 clinical trial for ELX-02 in cystic fibrosis, although enrollment is paused due to COVID-19. As of March 31, 2020, Eloxx had $44 million in cash, sufficient to fund operations through 2021. The company reported a net loss of $13.9 million for the quarter, including $4.0 million in restructuring charges. Preclinical studies on autosomal dominant polycystic kidney disease and inherited retinal disorders are progressing.